Premium
Pregnancy outcomes in women with Familial Mediterranean Fever receiving colchicine: Is amniocentesis justified?
Author(s) -
BenChetrit Eli,
BenChetrit Avraham,
Berkun Yackov,
BenChetrit Eldad
Publication year - 2010
Publication title -
arthritis care and research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.032
H-Index - 163
eISSN - 2151-4658
pISSN - 2151-464X
DOI - 10.1002/acr.20061
Subject(s) - familial mediterranean fever , colchicine , medicine , amniocentesis , pregnancy , obstetrics , cohort , gynecology , disease , prenatal diagnosis , fetus , biology , genetics
Objective To evaluate the outcome of pregnancies in women with familial Mediterranean fever (FMF) who are taking colchicine, and to reconsider the justification for amniocentesis in these women. Methods The outcome of 179 pregnancies in a group of women with FMF taking colchicine was compared with the outcome of 197 pregnancies in women with FMF who did not take colchicine during pregnancy and with 312 pregnancies in another cohort of healthy pregnant women of similar age and ethnicity. Results There was no difference in the 3 groups regarding early abortions, late abortions, or congenital malformations. There was a mild trend towards a better outcome for the colchicine‐treated group but these results did not reach statistical significance. Conclusion Treatment with colchicine during pregnancy in patients with FMF is beneficial in controlling the disease while not affecting the outcome of the pregnancy; therefore there is no justification for recommending amniocentesis in women taking colchicine solely because of this treatment.